Clinical outcomes of stereotactic body radiotherapy for de novo pulmonary tumors in patients with completely resected early stage non-small cell lung cancer

Figures & data

Table 1 Baseline characteristics (N=33)a

Characteristics	Number (%)/median (range)
Sex
Male	22 (66.67)
Female	11 (33.33)
Age at operation for first lung cancer (years)	64 (38–78)
Age at SBRT (years)	68 (40–82)
Interval between operation and SBRT (months)	24 (3–144)
KPS at SBRT
≥80	29 (87.88)
<80	4 (12.12)
Smoking status
Past or current smoker	10 (30.30)
Never smoker	21 (63.64)
Unknown	2 (6.06)
FEV1% predicted, %	73.2 (37.6–96.02)
Histology type of first lung cancer
Squamous cell carcinoma	11 (33.33)
Adenocarcinoma	20 (60.61)
Others	2 (6.06)
Histology type of second lung cancer
Squamous cell carcinoma	7 (21.21)
Adenocarcinoma	15 (45.45)
Unknown	11 (33.33)
Pathological stage of first lung cancer
IA/IB/IIA/IIB/unknowna	3 (9.09)/11 (33.33)/11 (33.33)/5 (15.15)/3 (9.09)
Surgical resection type
Lobectomy	21 (63.64)
Sublobectomy (segmentectomy or wedge resection)	10 (30.30)
Atypical resection	2 (6.06)
Surgical approach
Thoracotomy	13 (39.39)
Video-assisted thoracoscopic surgery	20 (60.61)
Locations of first lung cancer and de novo pulmonary tumors
In the same lobe	4 (12.12)
In the same hemithorax but different lobes	8 (24.24)
In the contralateral	21 (63.64)
Maximum recurrent tumor diameter (mm)	16.85 (4.00–55.60)
GTV (cm^3)	3.45 (0.38–61.85)
PTV (cm^3)	11.80 (2.62–105.35)
Volume of lung (cm^3)	2,778.06 (1,672.26–5,495.57)
Mean lung dose (Gy)	3.12 (1.52–9.66)
V20 of lung (%)	3.25 (1.00–20.00)
V30 of lung (%)	1.50 (0.50–16.00)
Prescription doses
65 Gy in 10 fractions (BED, 107.25 Gy)	1 (3.03)
50 Gy in 5 fractions (BED, 100 Gy)	19 (57.58)
60 Gy in 10 fractions (BED, 96 Gy)	10 (30.30)
50 Gy in 10 fractions (BED, 75 Gy)	3 (9.09)

Note:

a Clinical staging was performed according to the eighth edition of the AJCC TNM staging system.

Abbreviations: AJCC, American Joint Committee on Cancer; BED, biologically effective dose; GTV, gross tumor volume; KPS, Karnofsky performance status; PTV, planning target volume; SBRT, stereotactic body radiation therapy; Vn, the percentage of organ volume receiving ≥n Gy.

Figure 1 Cumulative incidences of LR and DM for all patients following SBRT (A) and Kaplan–Meier curves showing OS and PFS for all patients following SBRT (B).

Abbreviations: DM, distant metastasis; LR, locoregional recurrence; OS, overall survival; PFS, progression-free survival; SBRT, stereotactic body radiotherapy.

Table 2 Adverse effects after SBRT

Adverse effectsa	Grade 1	Grade 2	Grade 3	Total
	n (%)	n (%)	n (%)	n (%)
Skin reaction	10 (30.30)	2 (6.06)	0	12 (36.36)
RP	17 (51.52)	6 (18.18)	2 (6.06)	25 (75.76)
Esophagitis	1 (3.03)	1 (3.03)	0	2 (6.06)
Fatigue	7 (21.21)	3 (9.09)	0	10 (30.30)
Chest wall pain	6 (18.18)	2 (6.06)	1 (3.03)	9 (27.27)
Rib fractures	4 (12.12)	3 (9.09)	0	7 (21.21)

Note:

a Adverse effects were graded according to the National Cancer Institute’s CTC Version 3.0.²⁶

Abbreviations: CTC, Common Toxicity Criteria; RP, radiation pneumonitis; SBRT, stereotactic body radiotherapy.

ZhengXSchipperMKidwellKSurvival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysisInt J Radiat Oncol Biol Phys201490360361125052562

 PubMed Web of Science ®Google Scholar